Quarterly Earnings

After its public debut, BBOT unveils exciting early data from three unique cancer drugs, including a first in pancreatic cancer, backed by a strong cash runway.

Americold holds its quarterly dividend steady at $0.23/share, signaling stability to investors while navigating industry headwinds with a new strategic plan.

Inuvo's stock faces uncertainty as a strategic pivot causes a steep Q4 revenue drop, betting its future on its privacy-focused IntentKey AI technology.

Automotive SaaS firm MotorK posts a dramatic financial turnaround, achieving positive cash flow in H2 2025 by leveraging AI and a bold customer strategy.

As Concentrix sets its Q1 earnings date, investors are watching closely to see if its AI-driven strategy can overcome market headwinds and cautious guidance.

The Bloomberg 500 adds 11 tech-heavy firms like Nebius Group and ASTS, signaling a major shift in market leadership driven by AI and digital infrastructure.

Beating Wall Street estimates with historic gross profits, the chipmaker leverages new capital and key partnerships to push its ultra-low-power tech deeper into AI.

With a melanoma drug on track for 2027 and a deep pipeline, Immatics' 2025 net loss is part of a larger strategy to dominate PRAME cancer therapy.

With mixed trial results for its obesity drug and rising costs, Skye Bioscience's upcoming 2025 earnings call is a pivotal moment for investors.

The burger giant defied economic headwinds in 2025, posting record growth thanks to a key acquisition, new stores, and a focus on affordability.

German defense tech firm RENK Group reports a record €1.37B revenue, fueled by a 24% surge in its defense business amid global geopolitical tensions.

Record sales of its Trio® fertilizer fuel a major financial turnaround, as the company makes significant strides in extracting battery-grade lithium.

Ellington Credit reports a Q4 net loss amid a tough CLO market, yet management sees a major buying opportunity as asset prices get a reality check.

As Jabil preps its Q2 FY26 report, investors watch to see if the AI boom can sustain its momentum amid global economic and supply chain pressures.

Canadian General Investments posts a 35.3% share price gain, yet its NAV lags the benchmark. A deep dive into its portfolio, leverage, and market position.

As markets grow top-heavy, Intech's math-driven ETFs gain traction by turning diversification and volatility into a systematic source of returns.

As its stock stumbles, web-game leader CTW heads to the Roth Conference to prove its unique anime IP and HTML5 model can deliver long-term growth.

With its lead drug for a rare blood cancer nearing European submission, Cellectar Biosciences advances its targeted radiotherapy platform on two fronts.

Despite a full-year GAAP loss, AFC declares a dividend and shifts its strategy post-BDC conversion. Can it resolve legacy loans and find new growth?

After a rough earnings report sent its stock tumbling, WEBTOON Entertainment heads to key investor conferences to pitch its long-term IP and creator vision.